Vejle Hospital

STOCKHOLM, Feb. 23, 2024 /PRNewswire/ -- FOURTH QUARTER (OCTOBER - DECEMBER 2023) Order intake SEK 317.7 M (514.4) Net sales SEK 299.6 M (264.4) Operating profit SEK 44.4 M (20.7) Profit after tax SEK 31.5 M (14.1) Earnings per share before/after dilution SEK 0.92 (0.41) Cash flow SEK 45.5 M (42.8) Order backlog SEK 1,864.4 M (1,940.1) at the end of the period TWELVE MONTHS (JANUARY - DECEMBER 2023) Order intake SEK 1,004.2 M (1,218.5) Net sales SEK 1,022.2 M (843.6) Operating profit SEK 114.9 M (42.7) Profit after tax SEK 81.6 M (23.8) Earnings per share before/after dilution SEK 2.38 (0.69) Cash flow SEK 190.3 M (46.8) The Board of Directors proposes an ordinary dividend of SEK 0.70 (0) per share which corresponds to 30 percent of the group profit for the period in accordance with the dividend policy. Additionally, the Board of Directors proposes an extra dividend of SEK 1.30 (0) per share. SIGNIFICANT EVENTS DURING THE FOURTH QUARTER RaySearch secured an order from Israel-based P-Cure and expanded collaboration focusing on advanced proton therapy solutions. Paul Scherrer Institute in Switzerland placed an order for RayStation. The Mass General Cancer Center in the US placed an order and thereby expanded its installation of RayStation to also include proton treatment planning. Vejle Hospital in Denmark became the first center in the world to use RayStation for an online adaptive treatment with augmented CBCT. The hospital chain Froedtert & Medical College of Wisconsin, US, placed an order for RayStation. SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD The number of radiation therapy centers that have chosen RayStation for treatment planning now exceeds 1,000. The Royal Marsden in the UK will be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch. RaySearch acquired the product DrugLog from Pharmacolog. FOR FURTHER INFORMATION, PLEASE CONTACT: Johan Löf, CEO Telephone: +46 (0)8 510 530 00, [email protected] Annika Blondeau Henriksson, Interim CFO Telephone: +46 (0)8 510 530 00, [email protected] The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 23, 2024 at 7:45 a.m. CET. WEBCAST CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch's year-end report for January-December 2023 at a webcast to be held in English on Friday, February 23, 2024 at 10:00-10:30 a.m. CET. Link to webcast: RaySearch Q4, 2023 You can also join the webcast by phone: Sverige: +46 (0) 8 505 100 31 UK: +44 (0) 207 107 06 13 US: +1 (1) 631 570 56 13 The following files are available for download: SOURCE RaySearch Laboratories

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that University Hospital of Southern Denmark in Vejle, Denmark has developed a new and groundbreaking workflow for adapting a patient's treatment plan during the first treatment session. The improved workflow is enabled by the adaptive replanning capabilities of RayStation®* and significantly saves time for the patient. The first patient was successfully treated on October 10. In this workflow a preliminary treatment plan is prepared on the already available diagnostic CT scan rather than acquiring an additional CT scan for the purpose of treatment planning, which is the standard method today. This marks a significant benefit to the patient that no longer needs to wait for the additional CT appointment. The plan prepared on the diagnostic CT scan cannot be used without modifications due to different patient positioning at image acquisition compared to treatment delivery. Thanks to the synthetic CT algorithm and fast adaptive replanning capabilities in RayStation, the CBCT of the first treatment fraction can be used for creating an adapted plan during the treatment session. In this workflow, the CBCT is augmented with use of the diagnostic CT, and a new plan is created, which is used in the first and any subsequent fractions. The first patient - a 65-year-old man diagnosed with metastatic prostate cancer - was successfully treated on October 10. The patient was prescribed a 30 Gy regimen over 10 fractions. His treatment employed a VMAT (volumetric modulated arc therapy) arc on an Elekta C-arm linac. In the current example, the online adaptation was motivated by differences in positioning at image acquisition and at treatment. The powerful tools in RayStation have the potential of also addressing other anatomical changes. Rune S. Thing, medical physicist at Vejle Hospital, says: "We are dedicated to pushing the boundaries of innovation for improved patient care and operational excellence. Our goal with the new workflow is to significantly reduce the time that a patient undergoing short-course palliative radiotherapy has to stay in the hospital." Johan Löf, founder and CEO, RaySearch, says: "Online adaptive has been a key focus for RaySearch for many years and I am impressed by the work that is done at Vejle. RayStation has very advanced tools available for taking online adaptive into clinical routine and the work done by Vejle is showcasing what groundbreakning possibilities our users have to further advance cancer treatments." For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected] The following files are available for download: SOURCE RaySearch Laboratories